Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.
This study aims to investigate the prognostic factors and long-term treatment outcome in patients with early stage nasal natural killer (NK)/T-cell lymphoma. Sixty-four patients were recruited in this study, whose clinical and laboratory data were collected from hospital records. Early stage (stage IE: 51, stage IIE: 13) nasal NK/T-cell lymphoma (NNTCL) was established according to Ann Arbor staging classification. Among these patients, 23 received radiotherapy (RT) alone, the remaining 41 cases were treated with radiochemotherapy (RCT) comprised of 1-6 cycles of anthracycline-based chemotherapeutic regimens. Results show that the median overall survival (OS) time was 41 months. The 5-year OS and progression-free survival rates were 59.2 and 52.3%, respectively. The 5-year OS rate for patients who received RT alone was 57.9%, whereas that for patients who received RCT was 61.5% (P = 0.47). There is no significant difference between two treatment modalities. Multivariate analysis showed that Eastern Cooperative Oncology Group performance status (PS) score > or = 2, local tumor invasion out of nasal cavity, and lower complete remission (CR) rates in the initial treatment were significant unfavorable independent prognostic factors. Taken together, our study suggests that RCT did not improve the survival rate of patients with early stage NNTCL. PS score before treatment, local tumor invasion out of nasal cavity, and CR rate of the primary treatment may be independent prognostic factors among the subtype lymphoma entity.
Ma
Hui-Hui
HH
Department of Radiation Oncology, First Affiliated Hospital, Anhui Medical University, Hefei, China.
Qian
Li-Ting
LT
Pan
Hai-Feng
HF
Yang
Lin
L
Zhang
Hong-Yan
HY
Wang
Zhi-Hua
ZH
Ma
Jun
J
Zhao
Yu-Fei
YF
Gao
Jin
J
Wu
Ai-Dong
AD
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009669:Nose Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011867:Radioisotope Teletherapy; D011882:Radiotherapy, High-Energy; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone; D011241:Prednisone
Blood. 1994 Sep 1;84(5):1361-92
8068936
Cancer. 1998 Aug 15;83(4):806-12
9708949
J Clin Oncol. 1998 Jan;16(1):70-7
9440725
Am J Surg Pathol. 1999 Nov;23(11):1356-69
10555004
J Clin Oncol. 2008 Sep 1;26(25):4124-30
18626005
Acta Oncol. 2001;40(1):19-23
11321654
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):31-8
17049184
Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):797-802
2004957
Oncol Rep. 2005 Feb;13(2):265-71
15643509
Cancer. 1998 Aug 1;83(3):449-56
9690537
Cancer. 1996 May 15;77(10):2137-49
8640683
Hematol Oncol. 1992 May-Aug;10(3-4):141-7
1398510
J Clin Oncol. 1995 Mar;13(3):666-70
7884427
Cancer Res. 1971 Nov;31(11):1860-1
5121694
J Clin Oncol. 2006 Jan 1;24(1):181-9
16382127
Br J Cancer. 2005 Apr 11;92(7):1226-30
15798768
Am J Surg Pathol. 2000 Nov;24(11):1511-7
11075852
Ann Oncol. 2001 Mar;12(3):349-52
11332147
Hum Pathol. 1999 Jul;30(7):849-55
10414505
Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90
12182990
Radiother Oncol. 2001 Dec;61(3):261-9
11730995
Acta Oncol. 1997;36(3):307-11
9208902
Blood. 2004 Jan 1;103(1):216-21
12933580
Leuk Lymphoma. 2006 Jul;47(7):1274-82
16923557
Leukemia. 2001 Jul;15(7):1123-6
11455983
J Clin Oncol. 1999 Dec;17(12):3835-49
10577857
J Clin Oncol. 1999 Apr;17(4):1244
10561185
Ann Oncol. 2004 Oct;15(10):1467-75
15367405
Cancer Chemother Rep. 1966 Mar;50(3):163-70
5910392
Blood. 2005 Dec 1;106(12):3785-90
16109779
Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):599-605
3417488
Int J Surg Pathol. 2004 Oct;12(4):375-87
15494863
J Clin Oncol. 2000 Jan;18(1):54-63
10623693
N Engl J Med. 1993 Sep 30;329(14):987-94
8141877
Radiother Oncol. 1996 Jan;38(1):1-6
8850419
Am J Surg Pathol. 1996 Jan;20(1):103-11
8540601
Clin Lab Haematol. 2000 Aug;22(4):215-20
11012633
Am J Pathol. 2001 Dec;159(6):2095-105
11733360